Ultragenyx Pharmaceutical | RARE - Assets


Ultragenyx Pharmaceutical reported $1.19B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Immunic USD 189.74M 165.69M Mar/2026
Insmed USD 2.23B 123.49M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Kyowa Hakko Kirin JPY 1.09T 42.56B Sep/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Moderna USD 13.47B 2.51B Sep/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026